Allelica

Executive Summary

Allelica is a clinical genomics company pioneering the use of polygenic risk scores (PRS) to assess disease risk across diverse populations. Founded in 2015 and headquartered in New York, the company develops software and diagnostic tools that integrate ancestry-aware PRS with standard clinical models, enabling early identification of high-risk individuals for conditions such as cardiovascular disease and breast cancer. By addressing the historical lack of diversity in genomic datasets, Allelica's platform aims to reduce health disparities and improve preventive care. The company's technology is validated for use in multiple ancestries, positioning it as a leader in equitable precision medicine. As a private entity, Allelica operates in the diagnostics category and has generated interest from biopharma and healthcare providers seeking to incorporate genomic risk assessment into routine care. With the growing adoption of PRS in clinical practice and increasing recognition of the need for diverse genetic data, Allelica is well-positioned to capture market share. The company's focus on actionable disease areas and its ancestry-aware approach differentiate it from competitors. However, as a private company with limited public information, its financial and operational metrics remain undisclosed. The conviction score reflects a promising technology and market opportunity, tempered by execution risks and the competitive landscape. Key upcoming catalysts include regulatory clearances, strategic partnerships, and validation studies that could significantly enhance Allelica's commercial trajectory.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for cardiovascular PRS test60% success
• Q4 2026Major partnership with a top-10 U.S. health system for PRS integration50% success
• Q2 2026Publication of multi-ancestry validation study in a high-impact journal70% success